These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35426371)

  • 1. Mitochondria and the future of RASopathies: the emergence of bioenergetics.
    Kontaridis MI; Chennappan S
    J Clin Invest; 2022 Apr; 132(8):1-5. PubMed ID: 35426371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models.
    Dard L; Hubert C; Esteves P; Blanchard W; Bou About G; Baldasseroni L; Dumon E; Angelini C; Delourme M; Guyonnet-Dupérat V; Claverol S; Fontenille L; Kissa K; Séguéla PE; Thambo JB; Nicolas L; Herault Y; Bellance N; Dias Amoedo N; Magdinier F; Sorg T; Lacombe D; Rossignol R
    J Clin Invest; 2022 Apr; 132(8):. PubMed ID: 35230976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.
    Klüppel M; Samavarchi-Tehrani P; Liu K; Wrana JL; Hinek A
    Eur J Hum Genet; 2012 Aug; 20(8):870-7. PubMed ID: 22317973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome.
    Wey M; Lee J; Jeong SS; Kim J; Heo J
    Biochemistry; 2013 Nov; 52(47):8465-79. PubMed ID: 24224811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation.
    Goodwin AF; Tidyman WE; Jheon AH; Sharir A; Zheng X; Charles C; Fagin JA; McMahon M; Diekwisch TG; Ganss B; Rauen KA; Klein OD
    Hum Mol Genet; 2014 Feb; 23(3):682-92. PubMed ID: 24057668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.
    Niihori T; Aoki Y; Okamoto N; Kurosawa K; Ohashi H; Mizuno S; Kawame H; Inazawa J; Ohura T; Arai H; Nabatame S; Kikuchi K; Kuroki Y; Miura M; Tanaka T; Ohtake A; Omori I; Ihara K; Mabe H; Watanabe K; Niijima S; Okano E; Numabe H; Matsubara Y
    J Hum Genet; 2011 Oct; 56(10):707-15. PubMed ID: 21850009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model.
    Tidyman WE; Goodwin AF; Maeda Y; Klein OD; Rauen KA
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 34553752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costello syndrome model mice with a Hras
    Katata Y; Inoue SI; Asao A; Kobayashi S; Terui H; Inoue-Shibui A; Abe T; Niihori T; Aiba S; Ishii N; Kure S; Aoki Y
    Cell Death Dis; 2020 Aug; 11(8):617. PubMed ID: 32792500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.
    Gripp KW; Sol-Church K; Smpokou P; Graham GE; Stevenson DA; Hanson H; Viskochil DH; Baker LC; Russo B; Gardner N; Stabley DL; Kolbe V; Rosenberger G
    Am J Med Genet A; 2015 Sep; 167A(9):2085-97. PubMed ID: 25914166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
    Rauen KA; Banerjee A; Bishop WR; Lauchle JO; McCormick F; McMahon M; Melese T; Munster PN; Nadaf S; Packer RJ; Sebolt-Leopold J; Viskochil DH
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):136-46. PubMed ID: 21495172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.
    Gremer L; De Luca A; Merbitz-Zahradnik T; Dallapiccola B; Morlot S; Tartaglia M; Kutsche K; Ahmadian MR; Rosenberger G
    Hum Mol Genet; 2010 Mar; 19(5):790-802. PubMed ID: 19995790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mice with an Oncogenic HRAS Mutation are Resistant to High-Fat Diet-Induced Obesity and Exhibit Impaired Hepatic Energy Homeostasis.
    Oba D; Inoue SI; Miyagawa-Tomita S; Nakashima Y; Niihori T; Yamaguchi S; Matsubara Y; Aoki Y
    EBioMedicine; 2018 Jan; 27():138-150. PubMed ID: 29254681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.
    Lorenz S; Lissewski C; Simsek-Kiper PO; Alanay Y; Boduroglu K; Zenker M; Rosenberger G
    Hum Mol Genet; 2013 Apr; 22(8):1643-53. PubMed ID: 23335589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel pathogenic variant in the HRAS gene with lethal outcome and a broad phenotypic spectrum among Polish patients with Costello syndrome.
    Pelc M; Ciara E; Jezela-Stanek A; Kugaudo M; Cieślikowska A; Jurkiewicz D; Janeczko M; Chrzanowska K; Krajewska-Walasek M; Skórka A
    Clin Dysmorphol; 2017 Apr; 26(2):83-90. PubMed ID: 28027064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.
    Rosenberger G; Meien S; Kutsche K
    Hum Mutat; 2009 Mar; 30(3):352-62. PubMed ID: 19035362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse models.
    Schreiber J; Grimbergen LA; Overwater I; Vaart TV; Stedehouder J; Schuhmacher AJ; Guerra C; Kushner SA; Jaarsma D; Elgersma Y
    Sci Rep; 2017 Apr; 7(1):1256. PubMed ID: 28455524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studying Metabolic Abnormalities in the Costello Syndrome HRAS G12V Mouse Model: Isolation of Mouse Embryonic Fibroblasts and Their In Vitro Adipocyte Differentiation.
    Fidan M; Chennappan S; Cirstea IC
    Methods Mol Biol; 2021; 2262():397-409. PubMed ID: 33977491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duplications in the G3 domain or switch II region in HRAS identified in patients with Costello syndrome.
    Nagai K; Niihori T; Okamoto N; Kondo A; Suga K; Ohhira T; Hayabuchi Y; Homma Y; Nakagawa R; Ifuku T; Abe T; Mizuguchi T; Matsumoto N; Aoki Y
    Hum Mutat; 2022 Jan; 43(1):3-15. PubMed ID: 34618388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.
    Gripp KW; Lin AE
    Genet Med; 2012 Mar; 14(3):285-92. PubMed ID: 22261753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal muscle pathology in Costello and cardio-facio-cutaneous syndromes: developmental consequences of germline Ras/MAPK activation on myogenesis.
    Tidyman WE; Lee HS; Rauen KA
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):104-14. PubMed ID: 21495178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.